GSK to present updates on its assiduity- leading contagious complaint portfolio at IDWeek 2022
First donation of RSV Aged Adult vaccine seeker’s vital phase III efficacity and safety data
New data showing Shingrix efficacity and safety over ten times
Results on perpetration of long- acting HIV treatment, Vocabria/ Rekambys, in clinical setting
Breadth of data presented demonstrates GSK’s moxie and commitment to precluding and treating contagious conditions
GSK plc( LSE/ NYSE GSK) will partake updates on its assiduity- leading contagious complaint channel and portfolio with 33 objectifications accepted for the Infectious Disease Society of America’s IDWeek 2022 periodic meeting in Washington, DC, US from 19- 23 October 2022. This will include the first donation of the results from the,000- party vital AReSVi- 006 phase III trial which is probing the efficacity and safety of GSK’s respiratory syncytial contagion( RSV) vaccine seeker for grown-ups progressed 60 times and over. The abstract summarising the efficacity data from AReSVi- 006 has been accepted for oral donation on 20 October 2022 at1.45 pm ET.
Buttressing the strength of GSK’s portfolio of vaccines, data from an extension study exploring the efficacity and safety of Shingrix over ten times will also be participated for the first time, furnishing farther substantiation on the duration of protection for grown-ups progressed 50 times and over. This long- term follow-up study from two former phase III clinical trials( ZOE- 50 and ZOE- 70), which originally demonstrated up to 97 efficacity( 1),( 2),( 3) in grown-ups progressed 50 times and aged, will be presented on 20 October 2022 at12.15 pm ET.
cessions also include donations from ViiV Healthcare, the global specialist HIV company maturity- possessed by GSK, with Pfizer,Inc. and Shionogi &Co.,Ltd. as shareholders, which will correspond of objectifications from the company’s different portfolio of innovative licensed treatment and forestallment options. ViiV Healthcare will partake results from its pioneering perpetration wisdom program that aims to identify successful styles of integrating its drugs for HIV treatment in the clinical setting. The CARISEL study evaluates the stylish approaches to enforcing Vocabria/ Rekambys( cabotegravir, rilpivirine; retailed as Cabenuva in the US) administered every two months into clinical practice in Europe. Clinical results will be presented at IDWeek followed by primary results of the study at HIV Glasgow.
Tony Wood, Chief Scientific Officer, GSK said “ We’re proud to partake new and instigative data from across our contagious complaint portfolio at this time’s IDWeek 2022 – leading with our RSV vaccine seeker for aged grown-ups, long- term data on Shingrix to help shingles, and perpetration data and real- world substantiation from our established HIV treatment portfolio. Discovering and developing innovative vaccines and drugs against contagious conditions is a crucial focus for us, and our longstanding moxie means we’re uniquely placed to help cover people. ”
GSK ID Week data summary
In addition to the vital phase III efficacity data, GSK will partake three fresh objectifications for its RSV OA vaccine seeker. One from a trial exploringco-administration of the RSV OA vaccine seeker with flu vaccination, and two from a phase III immunogenicity and safety trial.
A farther 17 objectifications by ViiV Healthcare have been accepted as bill and oral donations, including data from the pieces cohort comparing real- world safety and effectiveness data in virologically suppressed grown-ups taking Dovato( dolutegravir, lamivudine) with those taking a bictegravir- or dolutegravir- grounded 3- medicine authority.( 4)
Four objectifications have been accepted as bill donations on Xevudy( sotrovimab), including data from the Fair Health study, a retrospective claims database analysis of high- threat cases with COVID- 19.
Another six objectifications have been accepted as bill donations for gepotidacin, a implicit first- in- class antibiotic.
About Contagious conditions
contagious conditions are a significant global health and profitable burden and are responsible for further than one in six deaths, worldwide.( 5) GSK’s commitment to precluding and treating contagious conditions is reflected by the broad portfolio of retailed products. Our global specialist company, ViiV Healthcare, is driven to deliver effective and innovative drugs for HIV treatment and forestallment, and our rich channel aims to address presently unmet medical requirements with high impact.
GSK is a global biopharma company with a purpose to unite wisdom, technology, and gift to get ahead of complaint together. Find out more atgsk.com/company